# Ashibio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ashibio

- Industry: Biotechnology
- Headquarters: Brisbane, US
- Website: www.ashibio.com
- Total disclosed funding: $29M
- Latest round: Series A (Mar 28, 2024)
- Investors on record: 4

## About

Founded in 2022 by CEO Pankaj Bhargava and based in California, US, Ashibio, Inc.'s focus is the research and development of novel therapies for rare bone and connective tissue diseases. In June 2024, Ashibio, Inc. raised an undisclosed amount of Series A funding led by investor MPM BioImpact, with participation from other investors Agent Capital, Mirae Asset Venture Investment, and YK Bioventures. The round was part of a larger USD 40 million seed and Series A funding.
 
Ashibio is engaged in the advanced development of several investigative therapies, including a potential treatment for fibrodysplasia ossificans progressiva (FOP), a rare genetic disease characterized by severe and progressive heterotopic ossification (HO), a pathological condition that causes abnormal bone formation in muscles, tendons, ligaments, and other soft tissues.
 
The company will use the June 2024 funding to advance the development of therapies for fibrodysplasia ossificans progressiva, initiate a Phase 2/3 trial of andecaliximab, and support pipeline programs for bone and connective tissue disorders.

## Funding rounds

- Series A, Mar 28, 2024, $29M — MPM BioImpact, Mirae Asset Venture Investment, Agent Capital, YK Bioventures

## Investors

- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series A
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series A
- YK Bioventures (https://capitalatlas.ai/funds/yk-bioventures) — Series A